-
Hemasphere: Real-world coverage of Polatuzumab in the treatment of relapsed/refractory DLBCL
Time of Update: 2023-01-04
： ， 。 ， ， Polatuzumab There is no clear standard of care for second-line and above treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), particularly in patients who are not transplant candidates 。 Recently approved therapies in Europe and the United States include polatuzumab vedotin in combination with bendamustine and rituximab (PolaBR), anti-CD19 monoclonal antibody tafasitamab in combination with lenalidomide, CD19 CAR T-cell therapy drugs axicabtagene ciloleucel, tislecagenleucel, and celiniso and loncastuximab tesirine.
-
How to understand lymphoplasmacytic lymphoma? This article is the best combing I've seen!
Time of Update: 2023-01-04
The infiltrating cells of LPL typically contain small B cells, plasmacyte-like lymphocytes, and plasma cells, which can involve the bone marrow and, rarelymph nodes, and/or spleen.
The infiltrating cells of LPL typically contain small B cells, plasmacyte-like lymphocytes, and plasma cells, which can involve the bone marrow and, rarelymph nodes, and/or spleen.
-
The Aspirin Episode of the Mystery of Platelet Disappearance
Time of Update: 2023-01-04
Patients due to radiotherapy and chemotherapy lead to bone marrow suppression, platelet production decreases, the original platelets in the peripheral blood and transfused platelets due to the side effects of drugs, increased destruction, shortened life, these factors lead to a combination of platelet count continues to be low.
-
Multiple myeloma: early intervention is essential!
Time of Update: 2023-01-04
1 Mar. 2021 11The approval of new myeloma drugs is based on its more reliable efficacy than the previous generation of drugs, patients should consider the whole course of treatment of the disease with holistic thinking in the initial stage of treatment, the choice of new drugs may have a higher initial treatment cost, but can effectively reduce the cost of later treatment, improve the quality of life throughout disease management, and significantly extend the overall survival.
-
Gut(IF=32) Zhengzhou University, Mingming, Zhaoming Zhang, et al. found that intestinal flora as a noninvasive diagnostic and prognostic biomarker for natural killer/T-cell lymphoma
Time of Update: 2022-12-04
On November 8, 2022, Zhang Mingming, Li Zhaoming of Zhengzhou University and Chen Weihua of Huazhong University of Science and Technology jointly published a report entitled "Gut microbiota as non- invasive diagnostic and prognostic biomarkers for natural killer/T- cell lymphoma" online at Gut (IF=32).
-
AJH: Predictors of anemia response to mometinib therapy in myelofibrosis and its impact on survival
Time of Update: 2022-11-26
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival [published online ahead of print, 2022 Nov 8].
Am J Hematol.
Am J Hematol.
Am J Hematol.
Am J Hematol.
1002/ajh.
1002/ajh.
-
A phase 3 study of adding high-dose methotrexate/whole-brain radiotherapy to temozolomide to treatment-naïve PCNSL failed
Time of Update: 2022-11-26
Primary CNS lymphomaPrimary central nervous system lymphoma (PCNSL) is an aggressive, extranodal non-Hodgkin lymphoma whose standard regimen includes whole-brain radiation therapy (WBRT) and high-dose
-
An example of thinking that blood types do not match positive and negative stereotypes
Time of Update: 2022-11-25
Figure 5 Figure 6 The test was continued using the Rh system typing detection card (gel method), and the red blood cell suspension of patients with a concentration of 3% was added to each column, and the microcolumn was flicked to mix well, and centrifuged for 5 minutes, as shown in Figure 7, anti-c, anti-D, and anti-E wells were positive.
-
Blood Adv: changes in pancreatic iron levels in patients with thalassemia major and their association with iron chelator therapy
Time of Update: 2022-11-25
Original source:Antonella Meloni, Laura Pistoia, et al, Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy, Blood Advances, 2022, https://doi.
Antonella Meloni, Laura Pistoia, et al, Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy, Blood Advances, 2022, https://doi.
-
【Blood Adv】CD19 CAR-T therapy for DLBCL patients without residual lymphoma is safe and effective
Time of Update: 2022-11-25
reported the outcome of tisagenlecleucel (tisa-cel) infusion in 7 patients without residual disease, and 5 patients (71%) remained in remission 1 year after treatment, and the peak and toxicity of CAR-T cell expansion were comparable to the original JULIET cohort, but the cases in this study were few and tisa-cel was used alone.
-
Transfus Med: Red blood cell transfusion is associated with an increased risk of visceral vein thrombosis in patients with cirrhosis
Time of Update: 2022-11-25
Figure 3: Dose-response relationship between blood transfusion and red blood cells Original source:Liu G, Lei P, Liao C, et al.
Figure 3: Dose-response relationship between blood transfusion and red blood cells Original source:Liu G, Lei P, Liao C, et al.
-
【Leukemia】First-line treatment and outcome after CD19-CAR-T treatment failure for large B-cell lymphoma
Time of Update: 2022-11-25
Study resultsPatient characteristics and outcomes A total of 305 patients (Table 1) at both centers received CD19-CAR-T (axi-cel [n = 116, 38%]; tisa-cel [n= 83，27%]； lisocel [n= 28，9%]； POC-CAR-T [n= 78,26%]), with a median age of 63 years, the predominant histologic subtype of LBCL is non-specific diffuse large B-cell lymphoma (n = 236,77%) 。 Most (211,69%) had previously received ≥ 3rd line therapy, 125 patients (41%) received > 3rd line therapy, most were stage III–IV (216.
-
The child suddenly lost blood sharply, and a look at the blood film solved the mystery
Time of Update: 2022-11-25
Figure 6Figure 6 Combined with the history of eating broad beans, soy sauce-colored urine, blood smear red blood cell morphology visible blister cells, and decreased G6PD, the final diagnosis was: G6PD deficiency.
-
AJCP: Direct thrombin inhibitor versus activated partial thromboplastin time in pediatric patients is monitored using calibrated diluted thrombin time
Time of Update: 2022-11-25
Figure 3: Example of direct thrombin inhibitor monitoring test values over time in patients taking a constant dose of argatroban.
Figure 3: Example of direct thrombin inhibitor monitoring test values over time in patients taking a constant dose of argatroban.
-
【Cancer】NOTCH mutation is a poor prognostic factor for treatment-naïve AML
Time of Update: 2022-11-25
058), but there were no significant differences in ORR and CR/CRi between the NOTCH wt and NOTCHmut groups in the low-intensity induction regimen。 Outcomes for patients with NOTCHmut Effect of NOTCH mut on survival: The median follow-up time for the NOTCH wt and NOTCH mut cohorts was 45.
-
Abdominal pain in January, the cause is this common blood disease
Time of Update: 2022-11-25
Push the film retest, it can be seen that the number of white blood cells is significantly increased, and the original cells are 9%: Visible at all stages of naïve granulocytes: Basophils 17%, a significantly increased number of platelets: Issue a prompt report: Other tests: Bone marrow was sent for examination, and it can be seen that hyperplasia is significantly active, and the blasts are 15%: Basophils 13%: Consider chronic myeloid leukemia-accelerated phase: Test case studies Flow cytometry showed 14.
-
The world's first "artificial blood" clinical trial, derived from a 2017 Nature sub-journal paper, may revolutionize the treatment of blood diseases
Time of Update: 2022-11-25
The research team used CRISPR-Cas9 gene editing technology to knock out five genes associated with blood group in the immortalized human adult red blood cell line (BEL-A) - FUT1, ACKR1, KEL, GYPB, RHAG, which encode the most common transfusion incompatible antigens.
-
Support Care Cancer: Symptom experience and self-management strategies during hospitalization in adult hematopoietic stem cell transplant patients: results from a qualitative longitudinal study
Time of Update: 2022-11-25
Understanding the symptom experience and self-management strategies of adult hematopoietic stem cell transplantation patients during hospitalization: findings from a qualitative longitudinal study.
Understanding the symptom experience and self-management strategies of adult hematopoietic stem cell transplantation patients during hospitalization: findings from a qualitative longitudinal study.
-
Review the summary of hot spots related to the 2022 CSH conference
Time of Update: 2022-11-15
For details, please poke: 2022 CSH| Professor Sun Chunyan: Application and research progress of circulating tumor plasma cell detection in the clinical diagnosis and treatment of multiple myelomahaemophiliaProfessor Hu Yu of the Union Medical College Affiliated to Tongji Medical College of Huazhong University of Science and Technology reviewed the development of hemophilia in the past 40 years, shared the current diagnosis and treatment status, and made a future prospect.
-
Express Significantly improves anemia symptoms! BMS innovative therapies reached the primary clinical endpoint of Phase 3
Time of Update: 2022-11-15
▎WuXi AppTec content team editorToday, Bristol-Myers Squibb (BMS) announced that its red blood cell maturation agent Reblozyl (luspatercept) has reached its primary endpoint in a Phase 3 clinical trial.
